TWI839623B - 治療神經退化性疾病之組合物及方法 - Google Patents

治療神經退化性疾病之組合物及方法 Download PDF

Info

Publication number
TWI839623B
TWI839623B TW110125694A TW110125694A TWI839623B TW I839623 B TWI839623 B TW I839623B TW 110125694 A TW110125694 A TW 110125694A TW 110125694 A TW110125694 A TW 110125694A TW I839623 B TWI839623 B TW I839623B
Authority
TW
Taiwan
Prior art keywords
alkyl
aryl
optionally substituted
group
tert
Prior art date
Application number
TW110125694A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216702A (zh
Inventor
麥克 Ｊ 布朗史丹
Original Assignee
美商愛治凡製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商愛治凡製藥公司 filed Critical 美商愛治凡製藥公司
Publication of TW202216702A publication Critical patent/TW202216702A/zh
Application granted granted Critical
Publication of TWI839623B publication Critical patent/TWI839623B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110125694A 2014-03-28 2015-03-30 治療神經退化性疾病之組合物及方法 TWI839623B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28
US61/971,862 2014-03-28
PCT/US2015/023060 WO2015148962A1 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases
WOPCT/US15/23060 2015-03-27

Publications (2)

Publication Number Publication Date
TW202216702A TW202216702A (zh) 2022-05-01
TWI839623B true TWI839623B (zh) 2024-04-21

Family

ID=54196457

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104110388A TWI736519B (zh) 2014-03-28 2015-03-30 治療神經退化性疾病之組合物及方法
TW110125694A TWI839623B (zh) 2014-03-28 2015-03-30 治療神經退化性疾病之組合物及方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW104110388A TWI736519B (zh) 2014-03-28 2015-03-30 治療神經退化性疾病之組合物及方法

Country Status (22)

Country Link
US (4) US9802925B2 (enExample)
EP (1) EP3122743B1 (enExample)
JP (2) JP7255967B2 (enExample)
KR (2) KR102725123B1 (enExample)
CN (3) CN116327950A (enExample)
AU (2) AU2015237253B2 (enExample)
BR (1) BR112016022575A2 (enExample)
CA (1) CA2944211C (enExample)
DK (1) DK3122743T3 (enExample)
ES (1) ES2939959T3 (enExample)
FI (1) FI3122743T3 (enExample)
IL (1) IL248074B (enExample)
MX (2) MX2021005502A (enExample)
MY (1) MY184878A (enExample)
NZ (1) NZ724718A (enExample)
PL (1) PL3122743T3 (enExample)
RU (1) RU2742773C2 (enExample)
SG (2) SG10202001065SA (enExample)
SI (1) SI3122743T1 (enExample)
TW (2) TWI736519B (enExample)
WO (1) WO2015148962A1 (enExample)
ZA (1) ZA201606673B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
AU2015237253B2 (en) * 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
TWI622380B (zh) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 生理訊號測量裝置及其血氧濃度演算方法
MY208313A (en) * 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury
WO2022140555A1 (en) * 2020-12-23 2022-06-30 Celgene Corporation Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1994004494A1 (en) 1992-08-13 1994-03-03 Warner-Lambert Company Tachykinin antagonists
CA2093125C (en) 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO1994001402A1 (en) 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
DE69405862T2 (de) 1993-05-06 1998-01-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AU1977997A (en) 1996-02-23 1997-09-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
WO1999006409A1 (en) 1997-07-30 1999-02-11 American Home Products Corporation Tricyclic vasopressin agonists
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
BR9812772A (pt) 1997-10-27 2000-10-10 Reddy Research Foundation "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos"
JP5049437B2 (ja) 1999-08-16 2012-10-17 リヴァアックス ファーマスーティカルズ，エルエルシー 神経治療のための合成物と方法
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
ES2666188T3 (es) 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
WO2003051314A2 (en) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060281728A1 (en) 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
JP2008540633A (ja) 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
JP5328349B2 (ja) * 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
WO2007109615A2 (en) * 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
WO2008034032A2 (en) 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
AU2007299822A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
EP2173745A2 (en) 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
US20090182011A1 (en) * 2008-01-16 2009-07-16 University Of Illinois Chicago Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) * 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
AU2015237253B2 (en) * 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
MY208313A (en) 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury

Also Published As

Publication number Publication date
US20180201608A1 (en) 2018-07-19
JP7255967B2 (ja) 2023-04-11
CA2944211C (en) 2022-10-04
SG10202001065SA (en) 2020-04-29
US20170174670A1 (en) 2017-06-22
AU2015237253B2 (en) 2019-11-14
MX2021005502A (es) 2023-01-16
ES2939959T3 (es) 2023-04-28
TW202216702A (zh) 2022-05-01
KR20220151037A (ko) 2022-11-11
TW201620902A (zh) 2016-06-16
SG11201608064WA (en) 2016-10-28
IL248074B (en) 2020-07-30
RU2016138349A (ru) 2018-05-04
US11319306B2 (en) 2022-05-03
US20200102294A1 (en) 2020-04-02
MX382453B (es) 2025-03-13
RU2742773C2 (ru) 2021-02-10
CN106459021A (zh) 2017-02-22
CN106459021B (zh) 2023-04-07
NZ724718A (en) 2023-04-28
DK3122743T3 (da) 2023-02-20
US10364236B2 (en) 2019-07-30
US20230123729A1 (en) 2023-04-20
EP3122743B1 (en) 2022-11-09
KR102725123B1 (ko) 2024-11-04
JP2017510645A (ja) 2017-04-13
AU2019253831A1 (en) 2019-11-14
MY184878A (en) 2021-04-29
RU2016138349A3 (enExample) 2018-10-26
US9802925B2 (en) 2017-10-31
EP3122743A4 (en) 2017-11-29
CA2944211A1 (en) 2015-10-01
CN116327950A (zh) 2023-06-27
KR20160130853A (ko) 2016-11-14
IL248074A0 (en) 2016-11-30
TWI736519B (zh) 2021-08-21
BR112016022575A2 (pt) 2017-08-15
ZA201606673B (en) 2019-06-26
JP2022116001A (ja) 2022-08-09
AU2019253831B2 (en) 2021-10-28
AU2015237253A1 (en) 2016-10-20
FI3122743T3 (fi) 2023-03-02
SI3122743T1 (sl) 2023-07-31
CN116139282A (zh) 2023-05-23
WO2015148962A1 (en) 2015-10-01
EP3122743A1 (en) 2017-02-01
MX2016012645A (es) 2017-01-11
PL3122743T3 (pl) 2023-05-02

Similar Documents

Publication Publication Date Title
AU2019253831B2 (en) Compositions and methods for treating neurodegenerative diseases
TW201919625A (zh) 用於治療腦損傷之組合物及方法
US10953001B2 (en) Methods for treating post traumatic stress disorder
HK1233638B (en) Compositions and methods for treating neurodegenerative diseases
HK1234030B (en) Compositions and methods for treating neurodegenerative diseases
HK1234030A1 (en) Compositions and methods for treating neurodegenerative diseases
HK1258668B (en) Compounds for use in the treatment of intermittent explosive disorder
HK1233638A1 (en) Compositions and methods for treating neurodegenerative diseases
HK1184640B (en) Methods for treating post traumatic stress disorder
HK1184640A (en) Methods for treating post traumatic stress disorder